Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O00142

UPID:
KITM_HUMAN

ALTERNATIVE NAMES:
2'-deoxyuridine kinase TK2; Deoxycytidine kinase TK2; Mt-TK

ALTERNATIVE UPACC:
O00142; B4DGJ7; B4DZK7; B7ZAB1; E5KNQ5; E9PH08; O15238

BACKGROUND:
The enzyme Thymidine kinase 2, mitochondrial (TK2), functions in the mitochondrial matrix to phosphorylate nucleosides, essential for mtDNA synthesis. Its activity is critical in cells with down-regulated cytosolic dNTP synthesis, relying on TK2 and DGUOK for mtDNA replication. TK2's alternative names include 2'-deoxyuridine kinase TK2 and Deoxycytidine kinase TK2.

THERAPEUTIC SIGNIFICANCE:
TK2's malfunction is associated with severe mitochondrial diseases such as Mitochondrial DNA depletion syndrome 2 and Progressive external ophthalmoplegia. These conditions underscore the enzyme's potential as a target for therapeutic intervention, highlighting the importance of further research into TK2.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.